JP2025512987A - 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法 - Google Patents

脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法 Download PDF

Info

Publication number
JP2025512987A
JP2025512987A JP2024559383A JP2024559383A JP2025512987A JP 2025512987 A JP2025512987 A JP 2025512987A JP 2024559383 A JP2024559383 A JP 2024559383A JP 2024559383 A JP2024559383 A JP 2024559383A JP 2025512987 A JP2025512987 A JP 2025512987A
Authority
JP
Japan
Prior art keywords
subject
lipid
dose
binding protein
apoa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512987A5 (cg-RX-API-DMAC7.html
Inventor
ツピン,キリル
ペロット,コンスタンス
バーバラス,ロナルド
Original Assignee
アビオニクス ファーマ エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アビオニクス ファーマ エスエー filed Critical アビオニクス ファーマ エスエー
Publication of JP2025512987A publication Critical patent/JP2025512987A/ja
Publication of JP2025512987A5 publication Critical patent/JP2025512987A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024559383A 2022-04-06 2023-04-06 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法 Pending JP2025512987A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328210P 2022-04-06 2022-04-06
US63/328,210 2022-04-06
PCT/IB2023/000183 WO2023194798A1 (en) 2022-04-06 2023-04-06 Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes

Publications (2)

Publication Number Publication Date
JP2025512987A true JP2025512987A (ja) 2025-04-22
JP2025512987A5 JP2025512987A5 (cg-RX-API-DMAC7.html) 2026-04-14

Family

ID=86732365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559383A Pending JP2025512987A (ja) 2022-04-06 2023-04-06 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法

Country Status (10)

Country Link
US (1) US20250255931A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504233A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025512987A (cg-RX-API-DMAC7.html)
KR (1) KR20240171131A (cg-RX-API-DMAC7.html)
CN (1) CN119317440A (cg-RX-API-DMAC7.html)
AU (1) AU2023251245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247588A1 (cg-RX-API-DMAC7.html)
IL (1) IL316100A (cg-RX-API-DMAC7.html)
MX (1) MX2024012302A (cg-RX-API-DMAC7.html)
WO (1) WO2023194798A1 (cg-RX-API-DMAC7.html)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
EP0751961A1 (en) 1994-03-22 1997-01-08 Research Corporation Technologies, Inc. Eating suppressant peptides
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
DK1290013T3 (da) 2000-04-21 2006-06-26 Amgen Inc Apo-A1/All-peptidderivater
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
WO2002038609A2 (en) 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
ES2304452T3 (es) 2001-08-20 2008-10-16 Csl Behring Ag Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas.
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
MXPA04011312A (es) 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
US6953840B2 (en) 2002-07-30 2005-10-11 Esperion Therapeutics, Inc. Methods of using non-human animal Apolipoprotein A-I protein
WO2004073684A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
JP5048486B2 (ja) 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
BRPI0614966A2 (pt) 2005-08-26 2016-09-13 Cerenis Therapeutics Holding S A vetor de expressão, bactéria de ácido lático, apolipoproteína isenta de endotoxina, e, método de produção de uma apolipoproteína isenta de endotoxina
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008104890A2 (en) 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
ES2601830T3 (es) 2007-10-23 2017-02-16 The Cleveland Clinic Foundation Apolipoproteína A-1 resistente a oxidantes y péptidos miméticos
MX2011008599A (es) 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
LT2673296T (lt) 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
SG11201506456VA (en) 2013-03-15 2015-09-29 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
KR20230004605A (ko) * 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
AU2021254856A1 (en) * 2020-04-16 2022-11-10 Abionyx Pharma Sa CER-001 therapy for treating kidney disease

Also Published As

Publication number Publication date
CN119317440A (zh) 2025-01-14
EP4504233A1 (en) 2025-02-12
US20250255931A1 (en) 2025-08-14
CA3247588A1 (en) 2023-10-12
WO2023194798A1 (en) 2023-10-12
KR20240171131A (ko) 2024-12-06
MX2024012302A (es) 2025-02-10
IL316100A (en) 2024-12-01
AU2023251245A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
US20240033322A1 (en) Methods for treating acute conditions using lipid binding protein-based complexes
Hu et al. Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis
Alexander et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model
JP2006508045A (ja) ヒト以外の動物のアポリポプロテインa−iタンパク質の使用方法
US12329800B2 (en) Annexin-coated particles
EP4648788A1 (en) Lipid binding protein molecule therapy
AU2019339528A1 (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
US20250255931A1 (en) Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
US20250360184A1 (en) Methods for treating acute conditions using lipid binding protein-based complexes
WO2025093929A1 (en) Lipid binding protein molecule therapy
US20250352613A1 (en) Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
Hardy et al. Could a Non-Cellular Molecular Interactome in the Blood Circulation Influence Pathogens’ Infectivity? Cells 2023, 12, 1699
Komalla Liposomes for Treatment of Inflammatory Diseases
Protocol Protocol Title: Effect of Interferon-gamma 1-b (IFN-γ lb) on Innate Immune Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260406